Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 80 years old, of any gender
• People who have been diagnosed with a type of liver cancer called hepatocellular carcinoma (either confirmed by tissue testing or by clinical assessment) and whose doctors have determined that a procedure called TACE (a treatment that delivers medicine directly to liver tumours through blood vessels) is needed
• People whose liver cancer falls into certain staging categories under a Chinese liver cancer classification system — either more advanced stages (Ⅱb or Ⅲa), or earlier stages (Ⅰa, Ⅰb, or Ⅱa) where surgery, liver transplant, or tumour ablation is not suitable or not desired
• People who have at least one liver tumour that has not yet been treated, measuring at least 1 cm and no more than 10 cm in size, as defined by a standard measurement system called mRECIST
• People who agree to take part in the study and sign a consent form

Who may not be able to join:

• People whose target tumour(s) have already received local treatments such as surgery, TACE, radiotherapy, or ablation, or who would need ablation or radiotherapy combined with TACE at the time of joining
• People with certain abnormal blood count results — specifically, very low white blood cell counts or very low platelet counts that cannot be corrected (with some exceptions for specific known causes)
• People with poor kidney function, as measured by specific blood and urine tests (confirm with trial site for exact values)
• People with blood clotting problems that cannot be corrected
• People with abnormally high calcium levels in the blood or a breathing-related acid imbalance that cannot be corrected
• People with severe whole-body wasting (cachexia) or failure of multiple organs
• People with serious infections that cannot be adequately controlled and who are therefore not suitable for TACE
• People with a complete blockage of the main blood vessel supplying the liver (portal vein) that cannot be treated or worked around
• People who are known to be allergic to or unable to tolerate certain medicines and materials used in this trial, including a type of chemotherapy drug (anthracyclines), calcium chloride, contrast dye used in imaging, or the materials used to block blood vessels during TACE
• People who are currently taking a type of heart medication called cardiac glycosides
• People whose tumour blood supply presents a risk of accidentally blocking blood flow to healthy areas, or who have blood vessel abnormalities that make the procedure unsafe or not possible
• People who have been diagnosed with another cancer within the past 2 years (except for certain skin cancers or early-stage cervical or breast cancers that have been fully removed)
• People whose cancer has spread widely or to distant parts of the body, and whose expected survival is less than 90 days
• People who are pregnant, breastfeeding, or planning to have a child
• People who have taken part in another clinical trial involving a drug or medical device within the past 30 days
• People considered unsuitable for the trial for any other reason, as assessed by the research team

Important: Always verify eligibility with the trial site directly before applying.